SNS812: A Breakthrough siRNA Drug for COVID-19 at ATS 2025 Conference SNS812, a novel siRNA drug co-developed by Oneness Biotech and Microbio, will present its promising COVID-19 data at ATS 2025, marking a milestone in antiviral therapy.

SNS812: A Breakthrough siRNA Drug for COVID-19 at ATS 2025 Conference #United_States #San_Francisco #Microbio #SNS812 #Oneness_Biotech